Xeris Pharmaceuticals last year snared approval for its first drug, a shelf-stable glucagon injector for hypoglycemia. Now it's deploying its formulation tech to hit another target—epilepsy—and the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results